LAROCHE RICHARD F JR - 05 May 2025 Form 4 Insider Report for NATIONAL HEALTHCARE CORP (NHC)

Role
Director
Signature
/s/ Richard F. LaRoche, Jr.
Issuer symbol
NHC
Transactions as of
05 May 2025
Net transactions value
+$323,200
Form type
4
Filing time
07 May 2025, 16:37:56 UTC
Previous filing
13 May 2024
Next filing
09 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LAROCHE RICHARD F JR Director 100 VINE STREET, MURFREESBORO /s/ Richard F. LaRoche, Jr. 07 May 2025 0001012859

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NHC Common Stock (held in my name or my wife's name) Options Exercise $323,200 +5,000 +2.5% $64.64 205,912 05 May 2025 Direct F1
holding NHC Common Stock (ROTH IRA) 115 05 May 2025 Direct
holding NHC Common Stock - Family LP (BFLP) 30,000 05 May 2025 GP
holding NHC Common Stock - Fam. Partnership (LR Ent.) 28,000 05 May 2025 Direct
holding NHC Common Stock - Fam. Partnership (LFLP) 96,000 05 May 2025 GP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NHC Option to Purchase Common Stock [2020 Grant] Options Exercise $0 -5,000 -100% $0.000000 0 05 May 2025 Common Stock 5,000 $64.64 Direct F1
holding NHC Option to Purchase Common Stock [2021 Grant] 7,500 05 May 2025 Common Stock 7,500 $71.64 Direct
holding NHC Option to Purchase Common Stock [2022 Grant] 7,500 05 May 2025 Common Stock 7,500 $69.19 Direct
holding NHC Option to Purchase Common Stock [2023 Grant] 7,500 05 May 2025 Common Stock 7,500 $55.75 Direct
holding NHC Option to Purchase Common Stock [2024 Grant] 7,500 05 May 2025 Common Stock 7,500 $96.03 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2020. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).